KALA (Kala Bio) Cyclically Adjusted PB Ratio: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KALA Kala Bio Inc KALA
21 GF Score
Price $0.51
! 1 Warning Sign
View Full Analysis

What is Kala Bio Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Kala Bio  (NAS:KALA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Kala Bio Cyclically Adjusted PB Ratio Related Terms


Kala Bio Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Kala Bio's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kala Bio Cyclically Adjusted PB Ratio Chart

Kala Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Kala Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

KALA vs GTBP, PHIO, ICU: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Kala Bio's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kala Bio Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kala Bio's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Kala Bio's Cyclically Adjusted PB Ratio falls into.


KALA
21GF Score
Kala Bio Inc KALA
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kala Bio Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Kala Bio's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Kala Bio's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.468/333.9520*333.9520
=0.468

Current CPI (Jun. 2026) = 333.9520.

Kala Bio Quarterly Data

Book Value per Share CPI Adj_Book
201603 0.000 238.132 0.000
201606 0.000 241.018 0.000
201703 -10,027.437 243.801 -13,735.311
201706 -227,307.354 244.955 -309,892.615
201709 10,151.393 246.819 13,735.077
201712 9,136.632 246.524 12,376.874
201803 8,172.208 249.554 10,936.011
201806 6,922.194 251.989 9,173.736
201809 5,572.407 252.439 7,371.747
201812 7,750.182 251.233 10,301.946
201903 6,077.336 254.202 7,983.960
201906 4,505.656 256.143 5,874.347
201909 3,116.048 256.759 4,052.868
201912 2,057.016 256.974 2,673.207
202003 6,481.101 258.115 8,385.319
202006 5,773.806 257.797 7,479.428
202009 4,728.301 260.280 6,066.642
202012 4,243.162 260.474 5,440.130
202103 4,301.850 264.877 5,423.693
202106 3,252.652 271.696 3,997.960
202109 2,361.097 274.310 2,874.460
202112 641.371 278.802 768.241
202203 -181.971 287.504 -211.370
202206 -1,085.467 296.311 -1,223.356
202209 -32.777 296.808 -36.879
202212 555.780 296.797 625.356
202303 507.971 301.836 562.020
202306 344.509 305.109 377.077
202309 208.365 307.789 226.077
202312 135.973 306.746 148.033
202403 118.252 312.332 126.438
202406 149.149 314.175 158.538
202409 74.390 315.301 78.790
202412 101.228 315.605 107.113
202503 44.232 319.799 46.190
202506 -24.000 322.561 -24.848
202509 -58.288 324.800 -59.930
202512 12.558 324.054 12.942
202603 0.579 330.213 0.586
202606 0.468 333.952 0.468

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Kala Bio Business Description

Other Exchanges 0JQ2:UK27F:Germany
Address 1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
21GF Score

Get the complete analysis for KALA

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.51
Price